Regulus Therapeutics this week announced that it grossed a total of $80.9 million from its recent initial public offering on the Nasdaq and other transactions.
The company went public in early October, floating its shares at $4 apiece, down from an originally expected $10 to $12 a share (GSN 10/4/2012). The total gross proceeds include $50.9 million from the public sale of common stock, $25 million from the sale of stock in a private placement with partner AstraZeneca, and $5 million from the sale of a convertible note in August to collaborator Biogen Idec.